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Panniculitides are a group of conditions character-
ized by inflammation of subcutaneous fat.1 Pancreatic
panniculitis is a rare lobular panniculitis that appears
in roughly 2% to 3% of patients with pancreatic
diseases, such as pancreatitis and pancreatic carci-
noma. Less commonly, pancreatic panniculitis has
been reported in transplant patients in association
with acute kidney or pancreas allograft rejection.2-5
Patients often present with tender erythematous
nodules, which may drain an oily substance, on the
distal lower extremities. Associated symptoms may
include acute arthritis, necrosis of abdominal or bone
marrow fat, pleural effusions, mesenteric thrombosis,
leukemoid reaction, and eosinophilia. The pathogen-
esis is hypothesized to involve release of pancreatic
enzymes, such as lipase, from the inflamed pancreas
into the portal and lymphatic circulation and subse-
quently deposited in distant sites where they hydro-
lyze subcutaneous fat.CASE REPORT
A 34-year-old African-American woman with a
history of a simultaneous pancreasekidney trans-
plant 6 years prior for complications of type I
diabetes mellitus and a rejected kidney allograft
presented to dermatology clinic with painful nodules
on her bilateral shins of 2 weeks’ duration. She
denied taking new medications, fever, abdominal
pain, arthralgia, or other systemic symptoms. She
was on a stable immunosuppressive regimen of
cyclosporine, 75 mg twice daily, and prednisone,
7.5 mg daily. On examination she was afebrile withthe University of Chicago, Department of Medicine, Section
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tender, deep 4- to 6-cm nodules scattered over the
anterior portion of her shins bilaterally (Fig 1).
A deep 4-mm punch biopsy with ample subcu-
taneous tissue was performed from the center of a
nodule on her left lateral shin. Histologic examina-
tion found septal panniculitis and an area of enzy-
matic fat necrosis with ghost cells and a neutrophilic
infiltrate (Fig 2).
Based on clinicopathologic correlation, a diag-
nosis of pancreatic panniculitis in the setting of a
pancreas transplant patient was made. The trans-
plant team was immediately contacted, and labora-
tory data were ordered, which showed an elevated
serum lipase of 2893 U/L (baseline, 130-300 U/L),
elevated serum amylase of 650 U/L (baseline, 70-300
U/L), and undetectable cyclosporine level at less
than 30 ng/mL (baseline, 40-100 ng/mL).
Quantitative polymerase chain reaction result for
serum cytomegalovirus (CMV) DNA was negative,
ruling out a potential etiologic agent for acute
allograft pancreatitis.6
The patient’s cyclosporine was increased from 75
mg twice daily to 100 mg twice daily with close
outpatient follow-up. After 1 week, her cyclosporine
level was 131 ng/mL, and her lipase and amylase
levels were down trending (Fig 3). By 8 weeks her
lipase and cyclosporine levels were at baseline, and
the shin nodules resolved without scarring.JAAD Case Reports 2015;1:101-5.
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Fig 2. Pancreatic panniculitis. Anucleated adipocytes
with thickened, shadowy cell membranes known as
‘‘ghost cells.’’
Fig 1. Pancreatic panniculitis. Multiple violaceous, tender,
4- to 6-cm nodules scattered on anterior shins, bilaterally.
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We present a case of pancreatic panniculitis in a
female pancreasekidney transplant recipient 6 years
posttransplant on standard immunosuppressive
medications. The diagnosis of allograft pancreatitis
and rejection presenting with pancreatic panniculitis
was supported clinically, histopathologically, and by
laboratory data. Although biopsy of the patient’s
pancreas allograft was not performed, acute allograft
rejection is supported empirically by the patient’s
dramatic increase in serum lipase and amylase
coinciding with undetectable cyclosporine levels.
In addition, increase of her immunosuppressive
medications was correlated with rapid normalization
of lipase and amylase levels, an elevation of cyclo-
sporine serum level to the therapeutic range, and
resolution of panniculitis.
A review of literature shows that this is the sixth
reported case of pancreatic panniculitis occurring
in a transplant recipient and the second in a
simultaneous pancreasekidney transplant recipient
(Table I).2-5,7 The previous 5 cases occurred from
1996 to 2010, during which period on average
more than 800 simultaneous kidneyepancreas,
more than 10,000 kidney, and several hundred
pancreas transplants were performed annually in
the United States,8 illustrating the rarity of reported
pancreatic panniculitis in a transplant patient.
Furthermore, it is one of the first few cases
associated with allograft rejection. In the 5 previ-
ously reported cases, all patients were 30 to 40
years of age, and 4 of the 5 patients were women.
Similar to our patient, all 5 patients presented with
classic painful, deep nodules on the legs, and all
but one lacked significant abdominal symptoms atinitial presentation. Reported timeframe of presen-
tation of cutaneous symptoms ranged from 3 to 21
months posttransplant. Acute pancreatitis was diag-
nosed in all 5 patients, and all required hospitali-
zation. The transplanted organ was biopsied in 3
patients, the results of which showed acute allo-
graft organ rejection; the patients responded well
to increased immunosuppression. One patient had
pancreatitis diagnosed secondary to medication
and improved after medication cessation. Imaging
results corroborated clinicopathologic findings in 4
cases. In the earliest reported case, the patient died
with a hemorrhagic and necrotic pancreas 1 month
after admission. The other 4 patients survived, with
normalization of laboratory values or imaging
confirmation of resolved inflammation within 3
weeks to 6 months.
Our case is notable in 2 aspects. Our patient
presented with pancreatic panniculitis 6 years after
her organ transplant, which is the longest posttrans-
plant presentation among the reported cases.
Second, our patient was treated exclusively in the
outpatient setting and responded rapidly to
increased immunosuppression, negating the need
for invasive or expensive testing; all 5 previously
reported patients required hospitalization. Our case
therefore illustrates that prompt diagnosis of cuta-
neous manifestations of pancreatic panniculitis in a
transplant patient and coordinationwith the patient’s
transplant team can lead to successful outpatient
treatment.
Dermatologists should therefore be aware of
characteristic painful erythematous nodules,
elevated serum pancreatic enzyme levels, and
possible associated symptoms such as arthralgias
as important clinical clues for pancreatic pannicu-
litis. Although abdominal symptoms and fever are
present in most pancreas transplant patients pre-
senting with acute graft pancreatitis,6 our case and
Fig 3. Increase of cyclosporine was correlated with rapid normalization of lipase and amylase
levels.
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patients present with pancreatic panniculitis,
abdominal symptoms are generally absent.
Furthermore, cutaneous lesions may be the pre-
senting symptoms in 40% of overall patients with
pancreatic disease (acute and chronic pancreatitis,
pancreatic carcinoma) and may precede abdominal
symptoms by 1 to 7 months.9,10 Histopathologic
findings of pancreatic panniculitis include a lobular
panniculitis initially and septal panniculitis later in
the course, with pathognomonic ‘‘ghost cells,’’
which represent coagulative necrosis of adipocytes
resulting in anucleated adipocytes with thickened,
shadowy cell membranes.11 Treatment for pancre-
atic panniculitis is mainly directed at managing the
underlying pancreatic disease.
We present this case to highlight several impor-
tant clinical aspects. First, when pancreatic panni-
culitis is seen in a pancreas transplant patient, organ
rejection should be strongly considered as the
underlying etiology. Second, dermatologic manifes-
tations are often the first sign, and abdominal pain
classically associated with pancreatitis is usually
absent. Finally, close communication between sub-
specialties allowed this patient to be treated exclu-
sively in the outpatient setting, which was
advantageous to the patient and cost saving to the
health care system.REFERENCES
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Table I. Summary of reported cases
Case Patient
Transplanted
organ(s)
Onset of
symptoms
posttransplant Immunosuppression Cutaneous findings
Abdominal
symptoms
before onset
of lesions
Abdominal
symptoms
after onset
of lesions
Serum
pancreatic
enzyme
levels
Langeveld-Wildschut
et al7 1996
40 yo F,
mesangiocapillary
glomerulonephritis
K AZA, CsA, PRED Multiple
erythematous
nodes on
lower legs
Wang et al2 2000 34 yo M, chronic
glomerulonephritis
K 3 mo AZA, CsA, CST Painful nodules
on legs
Right lower
quadrant
distension
Not
reported
Elevated
AMY, LIP
Echeverrıa et al3
2001
42 yo F, SLE K Not
reported
AZA, CsA, PRED Painful nodules
on legs
None Pain,
vomiting
Elevated
AMY, LIP
Pike et al4 2006 49 yo F, chronic
kidney
insufficiency, DM I
SPK 5 mo CsA, PRED, MMF Painful nodules
on knees and
lower legs
None None Elevatd
AMY, LIP
Prikis et al5 2010 40 yo F, DMI PAK 21 mo MMF, PRED, TAC Painful nodules
on legs and
feet
None None Elevated
AMY, LIP
Current study 34 yo F, DMI SPK 6 y CsA, PRED Painful nodules
on legs
None None Elevated AMY, LIP
AMY, Amylase; AZA, azathioprine; CMV, cytomegalovirus; CsA, cyclosporine; CST, corticosteroid; CT, computed tomography; DMI, diabetes
mellitus type I; K, kidney; LIP, lipase; MMF, mycophenolate mofetil; PAK, pancreas after kidney; PRED, prednisone; SLE, systemic lupus
erythematosus; SPK, simulatenous pancreasekidney; TAC, tacrolimus; U/S, ultrasound scan.
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Other findings
Treatment
setting
Prior transplanted
organ history
Transplant
organ statu
during episo
Inpatient
U/S and CT of
kidney showed
urinoma
Inpatient Not reported Biopsy prove
acute ren
allograft
rejection
Fever, malar
telangectasia,
tender cervical
lymphadenopathy,
right lobe
hepatomegaly,
bilateral acute
ankle arthritis,
CT shows
pancreatic
enlargement
Inpatient History of chronic
kidney rejection
Kidney not
biopsied
Elevated creatinine,
CT evidence of
allograft
pancreatitis
Inpatient Not reported Biopsy-prove
moderate
acute cell
renal allog
rejection
CT evidence of
allograft
pancreatitis
Inpatient Previously treated
for acute renal
and panc
rejection,
CMV viremia
Biopsy prove
severe ac
pancreas
allograft
rejection
Undetectable CsA
level
Outpatient Rejected kidney
allograft s/p
nephrectomy
Pancreas not
biopsy
Table I. Cont’d
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s
de CMV infection Diagnosis Treatment Outcome
Pancreatitis Patient died with
hemorrhagic and
necrotic pancreas
1 mo after admission
n
al
Acute CMV viremia Acute pancreatitis
possibly secondary
to medication or
CMV in setting of
acute renal graft
rejection and
CMV infection
Ganciclovir, OKT3 Lab values normalized
after 3 weeks,
commenced
hemodialysis therapy
for irreversible kidney
graft failure
History of CMV
chorioretinitis,
was not checked
during episode
Acute pancreatitis
secondary to
medication
(AZA and CsA)
Stop AZA and
CsA, continue
PRED at low
dose
Symptoms resolved over
6 months, pancreatic
enzymes normalized,
CT showed residual
pancreatic calcifications
n
ular
raft
Not present
during episode
(negative pp65)
Acute pancreatitis
in setting of biopsy
proven kidney
allograft rejection
and presumed
acute pancreas
allograft rejection
Dexamethasone,
switched CsA
to TAC; MMF
tripled; started
thymoglobulin
then OKT3
MR imaging back to
baseline after 2 months;
allograft pancreatectomy
after 17 months; no
residual exocrine
pancreas function;
has foci of residual
B-islets
n
ute
Prior history but
not present
during episode
(checked)
Acute pancreatitis in
setting of
pancreatic allograft
rejection
Octreotide, high
dose steroids,
plasmapheresis,
intravenous
immunoglobulin,
rituximab
Good graft function 2 years
later
Not present
(checked)
Acute pancreatitis in
setting of presumed
pancreatic allograft
rejection
Increase CsA Symptoms resolved over 2
months; allograft
pancreas failure
5 months later
